Scout Clinical and ICON Findings From Rare Disease Trial Participant Focus Group
Scout Clinical, a provider of comprehensive clinical trial patient services, has announced the results of their rare disease clinical trial patient focus group. Conducted in partnership with ICON plc, the initiative sought to amplify the voices of those whose lives are touched by rare diseases.
The information from these focus groups addresses the gap between the experiences and perceptions of patients and the participation support services provided to them during clinical trials. The series found:
- Rare disease trial participation exposes participants to significant pressures across a variety of categories—including financial, physical, logistical, psychological and emotional—all incremental to the burdens participants already bear by virtue of living with a rare disease.
- Trial participation support services had effectively helped respondents overcome barriers to participation.
- Fully 30% of participants identified emotional support/counseling as a service that could make it easier for them to participate in a clinical trial.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
